New Mexico Educational Retirement Board lowered its position in Celgene Corporation (NASDAQ:CELG) by 7.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 72,630 shares of the biopharmaceutical company’s stock after selling 6,200 shares during the period. New Mexico Educational Retirement Board’s holdings in Celgene Corporation were worth $9,835,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Celgene Corporation during the 1st quarter valued at $118,000. Acropolis Investment Management LLC purchased a new stake in Celgene Corporation during the 2nd quarter valued at $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Celgene Corporation by 47.5% during the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 380 shares during the last quarter. Oakworth Capital Inc. boosted its stake in Celgene Corporation by 11.7% during the 2nd quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 127 shares during the last quarter. Finally, Smithfield Trust Co. boosted its stake in Celgene Corporation by 35.7% during the 2nd quarter. Smithfield Trust Co. now owns 1,229 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 323 shares during the last quarter. 79.24% of the stock is owned by institutional investors.
A number of equities analysts have recently issued reports on the company. Morgan Stanley downgraded Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research note on Thursday, October 5th. William Blair restated an “outperform” rating on shares of Celgene Corporation in a research note on Monday, June 26th. Cantor Fitzgerald restated a “buy” rating on shares of Celgene Corporation in a research note on Monday, August 28th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and raised their price target for the stock from $96.93 to $131.70 in a research note on Friday, June 30th. Finally, BidaskClub upgraded Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and twenty-three have issued a buy rating to the stock. Celgene Corporation has a consensus rating of “Buy” and an average target price of $151.53.
Celgene Corporation (NASDAQ:CELG) opened at 138.86 on Wednesday. The company has a 50 day moving average price of $141.03 and a 200 day moving average price of $130.15. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $147.17. The firm has a market capitalization of $108.64 billion, a P/E ratio of 43.00 and a beta of 1.88.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.44 earnings per share. On average, equities analysts forecast that Celgene Corporation will post $7.32 EPS for the current fiscal year.
In related news, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last three months, insiders sold 46,233 shares of company stock valued at $6,268,259. Company insiders own 0.95% of the company’s stock.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.